Sentences with phrase «cancer research program as»

Not exact matches

The co-ordinator of the federal cancer program refers to it as «the most challenging but the most frustrating area of research today.»

As part of the fight to help eradicate breast cancer, Devotion Spirits, Inc., will donate proceeds from every bottle of Devotion Vodka's Perfect Cosmo sold (both on - premise and off - premise) throughout the month of October to the Pink & Bloom Foundation, a 501c3 organization committed to raising funds for cancer research and advocacy programs.

SUNY Chancellor Nancy Zimpher said cuts to programs that help disadvantaged high school students gain the opportunity to attend college, as well as reductions to federal college aid and cuts to medical research, including cancer research, would have a huge negative impact on New York's colleges.

SUNY Chancellor Nancy Zimpher says cuts to programs that help disadvantaged high school students gain the opportunity to attend college, as well as reductions to federal college aid, and cuts to medical research, including cancer research, would have a huge negative impact on New York's colleges.

At the Fred Hutchinson Cancer Research Center (FHCRC), there has been a strong center - driven effort to provide resources for interdisciplinary research training, such as establishing the Joint Degree and Dual Mentor pResearch Center (FHCRC), there has been a strong center - driven effort to provide resources for interdisciplinary research training, such as establishing the Joint Degree and Dual Mentor presearch training, such as establishing the Joint Degree and Dual Mentor programs.

In his day job, at the University of Texas MD Anderson Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortCancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortcancer mortality.

NIH supports both innovation and «optimization that can benefit patients — such as making a cancer drug less toxic or more potent,» says Andilibi, now program director of the US National Cancer Institute's Small Business Innovation Research (SBIR) Development Center in Bethesda, Marcancer drug less toxic or more potent,» says Andilibi, now program director of the US National Cancer Institute's Small Business Innovation Research (SBIR) Development Center in Bethesda, MarCancer Institute's Small Business Innovation Research (SBIR) Development Center in Bethesda, Maryland.

«As someone who researches pancreatic cancer, I think this discovery is significant because it defines mechanisms that lead to this cancer in ways that we didn't know about before,» says Firpo, who's also a member of the Pancreas Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer Instcancer, I think this discovery is significant because it defines mechanisms that lead to this cancer in ways that we didn't know about before,» says Firpo, who's also a member of the Pancreas Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer Instcancer in ways that we didn't know about before,» says Firpo, who's also a member of the Pancreas Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer InstCancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer InstCancer Institute.

The MD / PhD program at UT Houston and the Anderson Cancer Center was designed to train investigators who could better bridge the gap between basic science and clinical research, and as an alternative to the traditional MSTP program model.

«We challenged a current dogma in the field that emphasized PLK1's role in mitosis (cell division) as a primary mechanism for cancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Medcancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of MedCancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of MedCancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Medicine.

Joining forces with dermatologists and oncologists from the University Hospital in Zurich and backed by the University Research Priority Program «Translational Cancer Research,» Sommer's team was able to demonstrate that, in melanoma cells, the epigenetic factor EZH2 controls genes that govern tumor growth as well as genes that are important for the formation of metastases.

What's really impressive about Babar's accomplishment is that he did the work for both papers — one on the role of a population of stem cells in lung cancer development (published in Cell) the other on gene expression in group A Streptococcus (published in PNAS)-- as a participant in summer undergraduate research programs.

«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a hematologist - oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of MeProgram and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Meprogram at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine.

The findings will be presented as part of a poster presentation by members of the Rutgers Cancer Institute Precision Medicine Program at the Annual Meeting of the American Association for Cancer Research (AACR) being held in New Orleans next month.

This complexity contributes to its aggressive nature and resistance to conventional therapies such as chemotherapy and radiation therapy,» says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at Massey Cancer Center, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of tResearch and co-leader of the Cancer Molecular Genetics research program at Massey Cancer Center, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of tresearch program at Massey Cancer Center, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of the VIMM.

«RNAi therapies are a unique approach to cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&cancer cell to block the expression of specific proteins involved in tumor growth.»

In its twenty years of operation, the NRSA program has made it possible for many thousands of talented individuals in the basic biomedical, behavioral, and clinical sciences to sharpen their research skills and to apply those skills to topics of special concern to the nation, such as aging, hypertension, the genetic basis of disease, acquired immune deficiency syndrome (AIDS), cancer, environmental toxicology, nutrition and health, and substance abuse.

Dr. Kunle Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy research program.

-- In a blog post, Jay Bradner, the former head of Dana - Farber Cancer Institute and the current president of Novartis Institutes for Biomedical Research, wrote that too many investment dollars have gone into redundant cancer programs, such as more checkpoint inhibitors, rather than going after tougher drug targets that might have a greater future iCancer Institute and the current president of Novartis Institutes for Biomedical Research, wrote that too many investment dollars have gone into redundant cancer programs, such as more checkpoint inhibitors, rather than going after tougher drug targets that might have a greater future icancer programs, such as more checkpoint inhibitors, rather than going after tougher drug targets that might have a greater future impact.

Check out her blog post, as well as the video the ACC played during the night, a reel highlighting the various programs, cutting - edge technology and approaches to cancer care, discoveries and patient voices, reminding everyone why it's so important to support research efforts.

The Center for Cancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurCancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recResearch (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recresearch program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer and prevent its recurrence.

The strength of our research and treatment programs was recognized early on by the National Cancer Institute, becoming one of the first to earn comprehensive cancer center status and recognition as a «Center of Excellence.&Cancer Institute, becoming one of the first to earn comprehensive cancer center status and recognition as a «Center of Excellence.&cancer center status and recognition as a «Center of Excellence.»

As one of the finest pediatric hematology - oncology fellowship programs in the nation, our centers are training fellows to obtain outstanding clinical and laboratory research knowledge, paving the future of pediatric cancer and blood disorder care.

PROVIDENCE, R.I. [Brown University]-- Little Rhody is packing a huge wallop against diseases such as malaria, cancer, autism, and preeclampsia in large part because of a National Institutes of Health program that has funded nine major biomedical research centers across the state in the last 15 years.

One of only 40 cancer centers in the country designated by the National Cancer Institute (NCI) as a Comprehensive Cancer Center, the Johns Hopkins Kimmel Cancer Center has active programs in clinical research, laboratory research, education, community outreach, and prevention and cocancer centers in the country designated by the National Cancer Institute (NCI) as a Comprehensive Cancer Center, the Johns Hopkins Kimmel Cancer Center has active programs in clinical research, laboratory research, education, community outreach, and prevention and coCancer Institute (NCI) as a Comprehensive Cancer Center, the Johns Hopkins Kimmel Cancer Center has active programs in clinical research, laboratory research, education, community outreach, and prevention and coCancer Center, the Johns Hopkins Kimmel Cancer Center has active programs in clinical research, laboratory research, education, community outreach, and prevention and coCancer Center has active programs in clinical research, laboratory research, education, community outreach, and prevention and control.

The GDC went live with approximately 4.1 petabytes of data from National Cancer Institute - supported research programs, including some of the largest and most comprehensive cancer genomics datasets in the world — such as The Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments — and more than 14,000 anonymized patient Cancer Institute - supported research programs, including some of the largest and most comprehensive cancer genomics datasets in the world — such as The Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments — and more than 14,000 anonymized patienresearch programs, including some of the largest and most comprehensive cancer genomics datasets in the world — such as The Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments — and more than 14,000 anonymized patient cancer genomics datasets in the world — such as The Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments — and more than 14,000 anonymized patient Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments — and more than 14,000 anonymized patienResearch to Generate Effective Treatments — and more than 14,000 anonymized patient cases.

This has included building programs in community - based participatory research, as well as Program - directed strategies on environmental links to, and disparities in, breast cancer.

Together, this translational program is developed within the National Cancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population atCancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population atcancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population at risk.

Research in the Immunology, Microenvironment and Metastasis program is aimed at 1) merging basic mechanistic understanding of multidisciplinary pathways of host - tumor interactions and metastatic dissemination with novel translational opportunities for diseases diagnosis and immunotherapy, as well as 2) investigating mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.

Fellows will have a basic translational research mentor from CSHL as well as a clinical translational mentor from Northwell Health Cancer Institute to guide the development of their clinical research training throughout this fellowship program.

Virginia Tech researchers, Wu Feng and David Mittelman, have won the first worldwide $ 100,000 research award from the NVIDIA Foundation, as part of its «Compute the Cure» program — an effort to fight cancer.

June 2013 — Byron Lee, MD, PhD, who completed his research year as part of the Urology residency program in the Genomic Medicine Institute under the mentorship of Angela Ting, PhD, won a second place Lower Memorial Award in basic science for a paper published in Cancer Rresearch year as part of the Urology residency program in the Genomic Medicine Institute under the mentorship of Angela Ting, PhD, won a second place Lower Memorial Award in basic science for a paper published in Cancer ResearchResearch.

From 1996 - 2003 he served as an Assistant Professor of Medicine in the Section of Oncology and as co-Director of the Immunology Research Program of the Yale Cancer Center.

In addition to her expertise in tumor biology and a broad network of connections with leading scientists and clinicians in cancer research and clinical oncology, Dr. Almog has extensive hands - on experience with a variety of techniques ranging from the molecular level (DNA, RNA and proteins) to tissue, organ and mouse models in cancer biology, as well as extensive experience in project management and program coordination.

At the Sidney Kimmel Comprehensive Cancer Center, Dr. Nelson has served as the Associate Director for Translational Research and the Co-Director of the Prostate Cancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns HoCancer Center, Dr. Nelson has served as the Associate Director for Translational Research and the Co-Director of the Prostate Cancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Research and the Co-Director of the Prostate Cancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns HoCancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns HoCancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns HoCancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns HoCancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Hocancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Hocancer - research programs at Johns research programs at Johns Hopkins.

Background In our institute, the first research program on disseminated tumor cells (DTC) detection in the bone marrow of early breast cancer patients was initiated in the late 90's; with about a thousand patients included, we constituted one of the largest cohort ever reported and contributed to the landmark report that established bone marrow DTC as a level - of - evidence 1 prognostic factor in early breast cancer (Braun, N Engl J Med 2005).

«As a prominent cancer researcher, he will broaden the scope and strengthen our research program.»

The American Cancer Society (ACS) Studies of Cancer Survivors (SCS) were funded as an intramural program of research conducted by the ACS Behavioral Researchresearch conducted by the ACS Behavioral ResearchResearch Center.

Steven Baylin's epigenetics research is recognized by the National Cancer Institute as the most outstanding in its SPORE (Specialized Program of Research Exceresearch is recognized by the National Cancer Institute as the most outstanding in its SPORE (Specialized Program of Research ExceResearch Excellence).

Dr. Lieping Chen currently serves as the United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology and Medical Oncology at Yale School of Medicine and co-Director of the Cancer Immunology Program of Yale Cancer Center in New Haven, CT..

Old, who also heads the Ludwig Institute for Cancer Research (LICR) New York Branch and has served for many years as director of LICR's worldwide scientific programs, says that, eventually, vaccines will treat a wide variety of cancer types, recruiting the immune system to stop the progression of patients» tumors and helping to fully stabilizing the diCancer Research (LICR) New York Branch and has served for many years as director of LICR's worldwide scientific programs, says that, eventually, vaccines will treat a wide variety of cancer types, recruiting the immune system to stop the progression of patients» tumors and helping to fully stabilizing the dicancer types, recruiting the immune system to stop the progression of patients» tumors and helping to fully stabilizing the disease.

That's why Idunn Technologies is collaborating with four other universities for six research programs, to go beyond yeast, and work with an animal model of aging, as well as two cancer models.»

«Through these interdependent programs as well as a variety of other initiatives designed to engender partnerships and foster cross-sector collaboration within the field, Cancer Research Institute will continue to be an engine of innovation and a source of leadership to the field,» O'Donnell - Tormey said.

These advocates discussed their work as part of the Scientist ↔ Survivor Program April 20 at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia.

As part of a nationally recognized cancer research and treatment center, the Melanoma / Skin Cancer Program conducts innovative research to understand how melanoma develops, and how to better prevent and trecancer research and treatment center, the Melanoma / Skin Cancer Program conducts innovative research to understand how melanoma develops, and how to better prevent and treCancer Program conducts innovative research to understand how melanoma develops, and how to better prevent and treat it.

As part of the SFB - TR36 Transregional Collaborative Research Center and other funding programs (Einstein Visiting Fellowship, BIH, the DKTK, and German Cancer Aid), we have been addressing the fundamental principles and clinical applications of T cell therapy.

Programs are clustered into Discipline - Based or Disease - Oriented and bring together investigators from all research disciplines (basic, population focused, and clinical) to tackle the challenges of tumor development and progression, diagnosis and treatment, as well as cancer control and disparities.

Dr. Adachi - Mejia, Assistant Professor of Community and Family Medicine at Dartmouth's Geisel School of Medicine, and member of Norris Cotton Cancer Center's Cancer Control Research Program, focuses her research on cancer risk prevention, such as physical activity and tobaccCancer Center's Cancer Control Research Program, focuses her research on cancer risk prevention, such as physical activity and tobaccCancer Control Research Program, focuses her research on cancer risk prevention, such as physical activity and tobaResearch Program, focuses her research on cancer risk prevention, such as physical activity and tobaresearch on cancer risk prevention, such as physical activity and tobacccancer risk prevention, such as physical activity and tobacco use.

The Cancer Imaging and Radiobiology Research Program continues to thrive as a multidisciplinary group of cancer researchers that includes faculty from The Geisel School of Medicine at Dartmouth, the Thayer School of Engineering, and the clinical departments of Medicine (Radiation Oncology), Surgery, and Radiology within Dartmouth - Hitchcock Medical Center (Cancer Imaging and Radiobiology Research Program continues to thrive as a multidisciplinary group of cancer researchers that includes faculty from The Geisel School of Medicine at Dartmouth, the Thayer School of Engineering, and the clinical departments of Medicine (Radiation Oncology), Surgery, and Radiology within Dartmouth - Hitchcock Medical Center (cancer researchers that includes faculty from The Geisel School of Medicine at Dartmouth, the Thayer School of Engineering, and the clinical departments of Medicine (Radiation Oncology), Surgery, and Radiology within Dartmouth - Hitchcock Medical Center (DHMC).

Earlier research suggests these compounds are able to negatively affect critical cancer cell mechanisms, such as those responsible for programmed cell death (apoptosis) and for proliferation.